Ionis (IONS) Reports Q4 2025 Earnings with Revenue Growth and Guidance on TRYNGOLZA
Ionis Pharmaceuticals (IONS) reported Q4 2025 earnings with total revenue of $944 million, a 34% increase year-over-year, driven by commercial product sales and R&D collaborations. The company noted a potential decline in TRYNGOLZA revenues ahead of the sHTG launch and provided guidance assuming a standard FDA review timeline for olezarsen.
Tickers: $IONS
Topics: FDA review guidance product sales R&D collaborations revenue growth